利拉鲁肽改善新诊断2型糖尿病伴代谢综合征患者的血糖及心脏代谢危险指标  

Improved glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes and metabolic syndrome treated with liraglutide

作　　者：张琼阁[1] 王超群[1] 陈海燕 叶菲[1] 宝轶[1] 石勇铨[1] 郑骄阳[1] 

机构地区：[1]第二军医大学长征医院内分泌科,上海200003

出　　处：《中国临床医学》2017年第2期229-232,共4页Chinese Journal of Clinical Medicine

基　　金：国家自然科学基金面上项目(81270890)~~

摘　　要：目的:探讨利拉鲁肽对新诊断2型糖尿病伴代谢综合征患者的血糖及心脏代谢危险指标的影响。方法:入选63例新诊断2型糖尿病(HbA1c7.5%~11%)伴代谢综合征患者,按1∶1随机分配到二甲双胍组(0.85g,口服,2次/d)和利拉鲁肽组(1.2mg,皮下注射,1次/d)。主要的研究终点是:治疗12周后两组代谢指标自基线的变化。结果:共60例患者完成研究。与基线相比,两组患者的体质量、体质指数(BMI)、腰围、空腹血糖、HbA1c、总胆固醇、低密度脂蛋白胆固醇、三酰甘油均下降(P<0.01)。与二甲双胍组相比,利拉鲁肽组在降低体质量、BMI、腰围方面作用更显著,差异有统计学意义(P<0.05)。两组患者无严重不良反应。结论:利拉鲁肽可改善新诊断2型糖尿病伴代谢综合征患者的血糖及心脏代谢危险指标水平。Objective： To discuss the effect of liraglutide o n glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes （T2DM） and metabolic syndrome （MS）. Methods： Sixty-three cases with newly diagnosed T2DM （HbAic 7. 5%-11%） and MS were selected,and randomly divided 1：1 into metformin group （0. 85 g,oral administration,two times a day） and liraglutide group （1. 2 mg,subcutaneous injection, one time a day）. The primary endpoint was change in metabolic parameters. Results ： Sixty patients completed the study. There wasa reduction in weight,body mass index, waist circumference, fasting glycemia, HbAic, total and LDL-cholesterol, and triglycerides in both groups（P〈0 . 01）. Liraglutide was superior to metformin in reducing weight, BMI, and waist circumference （P〈0 . 05）. T h ere was no adverse effect in two groups. Conclusions ： Liraglutide is associated with improved glycemic control and reduction of cardiometabolic risk factors in newly diagnosed T2DM and the MS.

关 键 词：2型糖尿病 代谢综合征 利拉鲁肽 二甲双胍 心脏代谢危险指标 

分 类 号：R587.1[医药卫生—内分泌]